Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2530 - An interim assessment of key biomarkers (programmed cell death receptor ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) in third-line therapy non-small cell lung cancer (NSCLC) patients: A Danish cohort study


08 Oct 2016


Poster Display


Deirdre Cronin-Fenton


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


D. Cronin-Fenton1, T. Dalvi2, E. Hedgeman3, M. Norgaard1, L. Pedersen1, K. Mortensen4, A. Midta5, N. Shire2, R. Brody2, J. Fryzek6, D. Lawrence7, J. Rigas8, D. Potter2, J. Walker9, A. Mellemgaard10, T.R. Rasmussen11, S. Hamilton-Dutoit4, H.T. Sørensen1

Author affiliations

  • 1 Clinical Epidemiology, Aarhus University Hospital, 8200 - Aarhus C/DK
  • 2 Medical Evidence & Observational Research, AstraZeneca, Gaithersburg/US
  • 3 Epidemiology, EpidStat Institute, Ann Arbor/US
  • 4 Institute Of Pathology, Aarhus University Hospital, Aarhus C/DK
  • 5 Personalised Healthcare And Biomarkers, AstraZeneca, Macclesfield/GB
  • 6 Epidemiology, Epidstat Institute, Rockville/US
  • 7 Biostatistics And Information Sciences, AstraZeneca, Cambridge/GB
  • 8 Geisel School Of Medicine, Dartmouth College, Hanover/US
  • 9 Personalised Healthcare And Biomarkers, AstraZeneca, Cambridge/GB
  • 10 Oncology, University Hospital Herlev, Herlev/DK
  • 11 Respiratory Medicine, Aarhus University Hospital, Aarhus C/DK


Abstract 2530


Among NSCLC patients who received third-line therapy, we examined the association of PD-L1 expression and EGFR mutations with survival.


Third-line therapy NSCLC patients diagnosed during 2001-2012 were selected from the Danish Lung Cancer Group Registry. We retrieved patient data from population-based medical registries, and paraffin-embedded tumor tissue from pathology archives. We assessed PD-L1 expression using the Ventana IHC (SP263) validated assay (using 25% cutoff for high versus low), and genotyped EGFR to identify mutations at Exon 18 (G719X (G719A, G719C, and G719S), Exon 19 (deletions and complex mutations), Exon 20 (S768I, T790M, and insertions), and Exon 21 (L858R) via a PCR-based kit. Follow-up was from third-line therapy start to the first of death, emigration, or 31/12/2014. We used Cox regression to compute hazard ratios (HR) and associated 95% confidence intervals (95% CI) for PD-L1 and EGFR.


Among 344 third-line therapy patients, 185 (54%) were men, 165 (48%) were aged >60 years at diagnosis, and the majority were ever-smokers. 200 (58%) had adenocarcinoma histology, 85 (25%) had high PD-L1 expression in their tumors and 27 (8%) had EGFR mutations. Compared to patients with wildtype EGFR tumors, those with EGFR mutations less often showed high PD-L1 expression (21%, 95%CI = (4%, 38%) versus 25%, 95%CI = (19%, 31%); Fisher's exact p-value = 0.81). Median overall survival differed little by PD-L1 status, but was longer in patients with mutant compared with wildtype EGFR. Neither PD-L1 expression nor EGFR mutations were significantly associated with survival.

N No. of deaths Median Survival (months) (95%CI) Adjusted HR* (95%CI)
PD-L1 low 249 208 8.0 (6.6, 9.1) ref.
PD-L1 high 85 72 8.3 (6.1, 11.6) 0.89 (0.68, 1.17)
Wildtype 260 213 7,7 (6.5, 8.8) ref.
Mutant 27 22 11.0 (6.9, 22.1) 0.79 (0.51, 1.24)

*Adjusted for age, sex, histology (adenocarcinoma versus other)


Our findings suggest no association of PD-L1 expression or EGFR mutations with survival in third-line therapy NSCLC patients.

Clinical trial identification

Not applicable

Legal entity responsible for the study





T. Dalvi: TD is an employee and shareholder of MedImmune/AstraZeneca. E. Hedgeman: Funding to support this work from AstraZeneca Inc., Gaithersburg, MD 20878. A. Midta, N. Shire, R. Brody, D. Lawrence, D. Potter, J. Walker: Employee and shareholder of AstraZeneca. J. Fryzek: JPF was employed by AstraZeneca, 2009-2011. JPF received funding to support this work from AstraZeneca Inc., Gaithersburg, MD 20878. J. Rigas: Consultant physician to AstraZeneca. A. Mellemgaard: Honoraria and/or travel expenses from Lilly, Boehringer Ingelheim, BMS, MSD. S. Hamilton-Dutoit: Research funding from AstraZeneca. Honoraria or consulting Amgen. H.T. Sørensen: Research funding from Epidstat. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings